Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Receivables - Other (2023 - 2025)

Historic Receivables - Other for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $3.9 million.

  • NewAmsterdam Pharma's Receivables - Other rose 13687.73% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 13687.73%. This contributed to the annual value of $1.7 million for FY2024, which is 9977.14% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Receivables - Other stood at $3.9 million, which was up 13687.73% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Receivables - Other peaked at $4.0 million during Q1 2024, and registered a low of $875000.0 during Q4 2023.
  • For the 3-year period, NewAmsterdam Pharma's Receivables - Other averaged around $2.4 million, with its median value being $1.9 million (2024).
  • The largest annual percentage gain for NewAmsterdam Pharma's Receivables - Other in the last 5 years was 13687.73% (2025), contrasted with its biggest fall of 6381.43% (2025).
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Receivables - Other stood at $875000.0 in 2023, then soared by 99.77% to $1.7 million in 2024, then skyrocketed by 123.05% to $3.9 million in 2025.
  • Its Receivables - Other was $3.9 million in Q3 2025, compared to $3.3 million in Q2 2025 and $1.4 million in Q1 2025.